Phase 2 data presented at ASCRS highlight consistent and statistically significantly sustained reductions in IOP (P<.0001) through 6 months, with clinically meaningful reductions of 24% to 30% achieved with a single travoprost intracameral implant (Paxtrava 26 µg, formerly OTX-TIC; Ocular Therapeutix). 

Statistically significant IOP changes from baseline were observed for every individual and mean diurnal measurement at week 2, week 6, week 12, month 4.5, and month 6 (P<.0001). It was generally well tolerated, with no impact on corneal health. 

Study investigator Mark Gallardo, MD, in practice at El Paso Eye Surgeons, said he is enthusiastic about the implant “because of the positive, durable IOP reductions, accompanied by a good overall safety profile.” Due to its consistent durability of IOP reduction and implant bioresorption, the implant shows potential for repeat dosing without stacking of implants, he noted.